Dr. Huyck is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
611 Fenwick Dr
Papillion, NE 68046Phone+1 402-593-3141
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2009 - 2012
- Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 2005 - 2009
- Creighton University School of MedicineClass of 2005
Certifications & Licensure
- IA State Medical License 2007 - 2026
- NE State Medical License 2006 - 2026
- IL State Medical License 2009 - 2014
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer Start of enrollment: 2010 Jan 18
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Start of enrollment: 2018 Oct 26
- Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
- Join now to see all
Publications & Presentations
PubMed
- 27 citationsRegorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase ...Marwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, Tim Larson, Allen L Cohn
Eclinicalmedicine. 2023-04-01 - 16 citationsThromboembolic and bleeding complications in acute leukemiaHau C. Kwaan, Timothy Huyck
Expert Review of Hematology. 2010-12-01 - 3 citationsPhase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).Walid L Shaib, Rupji Manali, Yuan Liu, Bassel El-Rayes, Patrick Loehrer
European Journal of Cancer. 2023-08-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: